Balmed Medical Company

Name

Balmed Medical Company

Legal name

Jilin Aodong Pharmaceutical Group Co., Ltd. (吉林尊龙·Z6药业集团股份有限公司)

Website

https://balmedeu.com

Company type

Public

Founded year

1996

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cold, Flu & Cough Remedies (HLAIADAB), OTC Pain Relief & Fever (Analgesics, Anti-inflammatory, Topical Pain Relief) (CRADAMAC), Specialty Pharmacy & Biologics Distribution (CRAOAHAD)

Keywords

• Pharmaceutical manufacturing
• Traditional Chinese medicine
• TCM formula granules
• Prescription drug distribution
• Health supplement products

Headquarters

HQ city

Kagithane

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Manufacturing - Prescription Drugs: Manufacturing and sales of prescription pharmaceutical products including modern Chinese medicines, biochemical drugs, and botanical chemical drugs. Major products include 安神补脑液, 血府逐瘀口服液, 龟芪参口服液, 养血饮口服液, and 46 exclusive varieties. Sales through pharmaceutical sales subsidiaries and direct hospital/retail pharmacy channels.
2. Pharmaceutical Manufacturing - OTC and Health Products: OTC medications and high-end healthcare products including deer antler products, ginseng products, and health foods. Revenue from product sales through retail channels and e-commerce platforms.
3. TCM Formula Granules: TCM formula granule products (中药配方颗粒) with over 500 market filing approvals. Growing business segment serving hospital and clinic dispensing needs.
4. Financial Investment Income: Returns from equity investments in financial assets including Guangfa Securities (as largest shareholder), Second Yiyao (as second largest shareholder), Nanjing Pharmaceuticals (as third largest shareholder), and Liaoning Chengda. Investment income supports core pharmaceutical operations.

Pricing tiers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Core offering

Balmed Medical Company (operating as Jilin Aodong Pharmaceutical Group) manufactures and distributes modern Traditional Chinese Medicine (TCM), biochemical drugs, and botanical chemical drugs through 6 specialized pharmaceutical manufacturing subsidiaries, supported by 627 drug approval numbers including 46 exclusive varieties and 211 products listed in the 2024 National Insurance Drug Catalog. Products are sold through 5 dedicated sales subsidiaries to hospitals (government tender procurement), retail pharmacy chains, and TCM formula granule dispensing institutions across China, with flagship offerings such as Anshen Bunao Liquid, Xuefu Zhuyu Oral Liquid, and Naoxin Shu Oral Liquid. The company also produces pharmaceutical excipients (corn starch, dextrin, sucrose), enzyme-based health products through a partnership with Japan's Da Gao Enzyme, and high-end healthcare products including deer antler and ginseng series, while maintaining strategic financial investments in Guangfa Securities, First Pharma, Nanjing Pharma, and Liaoning Chengda.

Product overview

Jilin Aodong Pharmaceutical Group is a vertically integrated pharmaceutical conglomerate with 21 subsidiaries, including 6 modern TCM, biochemical, and phytochemical drug manufacturing companies; 1 R&D company; 5 pharmaceutical sales companies; 5 pharmaceutical support companies; 2 high-end health product companies; 1 toll road company; and 1 Hong Kong-based international subsidiary. The company holds 627 production approval numbers (314 TCM and 313 chemical drug approvals), including 46 exclusive varieties and exclusive dosage forms. Its portfolio spans 16 therapeutic categories: star/star products, cardiovascular, tonic supplements, women's and children's health, hepatobiliary and gastrointestinal, antipyretic analgesics, injectable solutions, rheumatology and bone disease, anti-infectives, cough and phlegm, urological medications, TCM decoction pieces, medical devices, health foods, health food and personal care products, and enzyme-based products. The company also manufactures pharmaceutical excipients (corn starch, dextrin, sucrose). Products include flagship oral liquids such as 安神补脑液 (brain health), 血府逐瘀口服液 (blood circulation), and 脑心舒口服液, alongside a broad range of TCM tablets, capsules, granules, syrups, and injectable preparations. The company operates under a 'pharmaceuticals + finance + big health' multi-wheel drive development model.

Differentiator

Problem solved

Functional benefit

Brands

• 安神补脑液 (Anshen Bunao Liquid): Flagship TCM product for sleep and brain health
• 鹿茸系列 (Deer Antler Series)
• 人参系列 (Ginseng Series)

Products and services

• Anshen Bunao Liquid (安神补脑液) A flagship TCM oral liquid formulation for insomnia and brain health support; one of the company's star products with over 42 years on the market. Distributed to hospitals (for insomnia and brain health), retail pharmacies (OTC), and patients seeking sleep and cognitive support.
• Xuefu Zhuyu Oral Liquid (血府逐瘀口服液)
• Naoxin Shu Oral Liquid (脑心舒口服液) An oral liquid formulation for supporting brain and cardiovascular health. Distributed through hospital and retail pharmacy channels targeting patients needing cerebrovascular and cognitive support.
• Injectable RNA 2-BP Su (注射用核糖核酸2-BP素) An injectable RNA preparation used in oncology supportive care. Targeted at hospitals and oncology treatment centers requiring specialty injectables.
• Zhenqi Fuzheng Granules (贞芪扶正颗粒) A TCM immunomodulatory granule available in various dosage strengths (15g, 5g, with sugar-free and sugared variants); a featured product. Distributed to hospitals and clinics for immunotherapy and adjunctive oncology care.
• Xiao'er Chaigui Tuire Oral Liquid (小儿柴桂退热口服液) A pediatric TCM oral liquid for relieving fever in children. Targeted at pediatric departments in hospitals, retail pharmacies, and parents of young children seeking traditional fever relief.
• Guishen Shen Oral Liquid (龟芪参口服液) A TCM tonic oral liquid containing turtle and astragalus extracts, used for restorative and tonic purposes. Distributed through hospital and pharmacy channels for patients needing tonic and qi-supplement therapy.
• Yangxue Yin Oral Liquid (养血饮口服液) A TCM oral liquid for nourishing blood (hematinic indication). Distributed through hospital and pharmacy channels for patients with blood deficiency and related conditions.
• Injectable Pingyangmycin Hydrochloride (注射用盐酸平阳霉素) An injectable antineoplastic agent (pingyangmycin hydrochloride) used in oncology. Targeted at hospital oncology departments requiring chemotherapy injectables.
• Shaofu Zhuyu Granules (少腹逐瘀颗粒) A TCM granule formulation for gynecological blood stasis conditions. Distributed through hospital OB/GYN departments and women's health clinics.
• Lingbei Zhike Syrup (羚贝止咳糖浆) A TCM cough syrup containing antelope horn and bulb fritillary. Distributed through hospital respiratory departments and retail pharmacies for cough and phlegm relief.
• Injectable Ademetionine Butanedisulfonate (注射用丁二磺酸腺苷蛋氨酸) An injectable hepatoprotective agent (ademetionine) used in liver disease treatment. Targeted at hospital hepatology departments.
• Jinqi Jiangtang Capsules (金芪降糖胶囊) A TCM capsule for lowering blood sugar, indicated for diabetes management. Distributed through hospital endocrinology departments and pharmacies.
• Yunkang Granules (孕康颗粒) A TCM granule for pregnancy health support. Distributed through hospital OB/GYN and maternal health clinics.
• Corn Starch (玉米淀粉) Pharmaceutical-grade corn starch used as an excipient in drug formulations. Sold to other pharmaceutical manufacturers as a raw material input.
• Dextrin (糊精) Pharmaceutical-grade dextrin used as a binding agent in solid dosage forms. Sold to other pharmaceutical manufacturers.
• Sucrose (蔗糖) Pharmaceutical-grade sucrose used as a sweetener and excipient in drug formulations. Sold to other pharmaceutical manufacturers.
• TCM Formula Granules (中药配方颗粒) A growing portfolio of over 500 TCM formula granule products approved for clinical dispensing, supporting personalized formula preparation in TCM hospitals and clinics. Sold to TCM hospitals, TCM clinics, and dispensaries for practitioner-prescribed dispensing.
• Aodong Enzyme Series (尊龙·Z6酵素) Enzyme-based health products including Aodong Enzyme, Ginseng Enzyme, and Matsutake Enzyme product series, developed through partnership with Japan's Da Gao Enzyme Co. Sold through retail pharmacy chains, health product distributors, and direct channels for consumer health supplementation.
• Medical Consultancy Services Medical product consultancy services for domestic and international markets, supporting hospital and partner institutions with pharmaceutical expertise, product guidance, and market access support.

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Six partnerships are on record, tiered core and strategic.

• 安徽中医药大学coreStrategic or Co-development Partner · 24 September 2024Strategic cooperation signing ceremony held September 24, 2024 at Anhui University of Chinese Medicine. Partnership focuses on formula granule project R&D, production, talent development, and standard improvement. Guo Shuqin (Vice Chairman and General Manager of Aodong Group, Chairman of Yanbian Pharmaceutical) signed on behalf of Aodong. Both parties committed to leveraging TCM characteristics and strengthening professional talent cultivation.
• 长春中医药大学coreStrategic or Co-development Partner · 23 September 2024Changchun University of Chinese Medicine President Leng Xiangyang led a delegation to Aodong on September 23, 2024 for产学研 cooperation research. Chairman Li Xiulin and Vice Chairman Guo Shuqin received the delegation. Discussions covered R&D achievement transformation, ginseng industrialization, talent cultivation, and industry-education integration. The university committed to supporting Aodong's technological, talent, and achievement needs to strengthen industry-university-research collaboration.
• 中国中医科学院strategicStrategic or Co-development PartnerStrategic cooperation with China Academy of Chinese Medical Sciences for seed resource research and achievement transformation for northern authentic TCM materials (北方道地药材). Aodong medicinal materials company established partnerships with the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences.
• 吉林农业大学strategicStrategic or Co-development PartnerPartnership with Jilin Agricultural University for northern authentic TCM material seed resource research and achievement transformation. Collaborated on core seed resource libraries, gene banks, specimen banks, and databases for ginseng and other key herbs.
• 日本大高酵素株式会社strategicStrategic or Co-development PartnerDeep cooperation with Japan's Dakao Enzyme Co. (大高酵素株式会社) in enzyme product development. Aodong Enzyme leveraged Dakao's enzyme expertise and combined with Changbai Mountain natural plant resources to develop Aodong Enzyme, Ginseng Enzyme, and Matsutake Enzyme product series.
• 吉林省药检院strategicStrategic or Co-development PartnerAodong Redstone Deer cooperated with Jilin Province Drug Inspection Institute to establish 'Jilin Provincial Drug Inspection Institute - Aodong Sika Deer Medicinal Parts Quality Analysis and Standard Research Center', supporting quality standards for deer antler medicinal products.

Scale indicators11 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Guangzhou Baiyunshan Pharmaceutical Holdings: Diversified Chinese pharmaceutical manufacturer combining TCM and Western medicine across hospital, retail, and wholesale channels with comparable scale and listed-company transparency.
• Zhejiang Conba Pharmaceutical: Chinese pharmaceutical company combining TCM and modern pharma products with hospital channel focus, comparable on regulatory asset base and TCM formula granule positioning.
• Yunnan Baiyao Group: Major Chinese TCM and herbal healthcare manufacturer with a similarly diversified branded product portfolio, hospital and retail distribution, and Time-honored Brand heritage. Closely comparable in business model, scale, and TCM-centric strategy.
• Shandong Dong-E E-Jiao: Specialty TCM manufacturer focused on a single hero raw material (donkey-hide gelatin) with strong brand equity and vertical raw-material integration — analogous to Aodong's deer antler and ginseng integration model.
• Beijing Tongrentang: Iconic Chinese TCM manufacturer with hospital and retail channels, branded specialty products, and similar regulatory asset base. Comparable on exclusive variety positioning and China Time-honored Brand status.
• China Resources Sanjiu Medical & Pharmaceutical: Large state-backed TCM and OTC pharmaceutical company with branded products in self-medication and hospital channels. Direct comparable on size, channel mix, and OTC/TCM product breadth.
• Pien Tze Huang (Zhangzhou Pien Tze Huang): Specialty branded TCM company with exclusive flagship formulations and strong hospital/retail presence. Comparable on Time-honored Brand heritage and exclusive-variety-driven pricing.

Broad incumbents

• Shanghai Pharmaceuticals Holding: One of China's largest pharmaceutical conglomerates with both manufacturing and distribution — broader portfolio than Aodong but directly comparable on integrated pharma-plus-distribution model.
• China Traditional Chinese Medicine Holdings (Sinopharm TCM): State-affiliated TCM conglomerate under Sinopharm covering TCM formula granules, finished dosage forms, and raw materials — overlapping with Aodong's TCM granule and botanical drug portfolio at larger scale.

Emerging players

• Jiangsu Hengrui Pharmaceuticals: China's leading specialty/innovative pharma company with strong hospital channel presence. Useful comparable for specialty pharma trajectory even though focused on innovative drugs rather than TCM.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/balmedmedical
• LinkedInlinkedin.com/company/balmed-medical-company

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Balmed Medical Company